BioLum Sciences

BioLum Sciences

Transforming Precision Drug Discovery and Early Detection of Disease

Founded 2015

Dallas, United States 5 employees Grant Total: $1.05M Biotechnology, Digital Health +2

BioLum Sciences is a biotechnology startup based in the United States that is focused on transforming precision drug discovery and early detection of disease. Leveraging biomarker analysis with an integrated approach, BioLum is providing highly-sensitive, selective assays and lab services to facilitate more efficient therapeutic R&D. The company's assays, with a primary focus on reactive oxygen, nitrogen, and sulfur species (RONSS), have surpassed gold standards and offer improved chemiluminescence, which eliminates background autofluorescence, ensuring superior accuracy and precision with broad specimen compatibility. Notably, BioLum collaborates with pharmaceutical companies and researchers in preclinical discovery and development. Its services range from biomarker analysis, compound library screening, and efficacy testing to early target identification and validation. The company's focus on reactive species, which are implicated in various diseases such as inflammation, cardiovascular, respiratory, neurological, and immune-related conditions, highlights the broad impact of its technology. In terms of financial backing, BioLum Sciences recently secured a $251.94K grant investment on 22 December 2021 from the National Institute of General Medical Science. This funding serves to support the company's continued advancement in precision medicine and early disease detection. With its innovative approach and industry relevance, BioLum Sciences presents a promising investment opportunity in the biotechnology and healthcare sectors.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$251.94K	1	National Institute of General Medical Science	22 Dec 2021
Grant	$224.81K	1	National Science Foundation	01 May 2020
Corporate Round	Undisclosed	1	Bayer	10 Oct 2019
Pre Seed Round	$572.30K	-		07 Sep 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

$251.94K

National Institute of General Medical Science

22 Dec 2021

Grant

$224.81K

National Science Foundation

01 May 2020

Corporate Round

Undisclosed

Bayer

10 Oct 2019

Pre Seed Round

$572.30K

07 Sep 2017

FAQ About BioLum Sciences

Transforming Precision Drug Discovery and Early Detection of Disease

BioLum Sciences was founded in 2015.

BioLum Sciences is headquartered in Dallas, United States.

BioLum Sciences operates in Biotechnology, Digital Health, Health Care and Medical Devices. Its work centres on Precision Medicine, Biomarker Analysis, Drug Discovery and Early Disease Detection.

BioLum Sciences has approximately 5 employees.

BioLum Sciences has completed 4 funding rounds, raising a total of $1.05M. The latest funding stage is Grant.

Top alternatives and competitors to BioLum Sciences include Chance Pharmaceuticals 畅溪制药, Spirometrix, Inc. (now Spirosure, Inc.), Amira Pharmaceuticals, Nicox, InterCure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

BioLum Sciences and Chance Pharmaceuticals 畅溪制药 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About BioLum Sciences

Funding Rounds & Investors (4)

BioLum Sciences Alternatives & Competitors

FAQ About BioLum Sciences